XML 79 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
Balance Sheet Details (Tables)
12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets as of December 31, 2023 and 2022 consisted of the following:

 

 

 

 

December 31,

 

 

December 31,

 

 

 

 

2023

 

 

2022

 

 

 

 

(in thousands)

 

Prepaid expenses

 

 

$

6,159

 

 

$

5,312

 

Purchased equipment deposits

 

 

 

3,856

 

 

 

 

Interest receivable

 

 

 

3,598

 

 

 

2,848

 

Grant receivable

 

 

 

9

 

 

 

1,029

 

Other current assets

 

 

 

2,105

 

 

 

1,990

 

Total

 

 

$

15,727

 

 

$

11,179

 

Schedule of Property and Equipment, Net

Property and equipment, net as of December 31, 2023 and 2022 consisted of the following:

 

 

 

December 31,

 

 

 

2023

 

 

2022

 

 

 

(in thousands)

 

Furniture and equipment

 

$

1,608

 

 

$

1,608

 

Computers and computer software

 

 

771

 

 

 

416

 

Lab equipment

 

 

25,110

 

 

 

13,100

 

Leasehold improvements

 

 

1,460

 

 

 

1,353

 

Manufacturing equipment and auxiliary

 

 

8,134

 

 

 

 

Manufacturing facility and equipment construction-in-progress (1)

 

 

51,815

 

 

 

 

Total property and equipment

 

 

88,898

 

 

 

16,477

 

Less: accumulated depreciation and amortization

 

 

(9,272

)

 

 

(6,117

)

Property and equipment, net

 

$

79,626

 

 

$

10,360

 

____________

(1)
See Note 4, Commercial Manufacturing and Supply Agreement, for further details.
Summary of Other Assets

Other assets as of December 31, 2023 and 2022 consisted of the following:

 

 

 

 

December 31,

 

 

December 31,

 

 

 

 

2023

 

 

2022

 

 

 

 

(in thousands)

 

Manufacturing facility construction buildout (1)

 

 

$

34,688

 

 

$

 

Long-term prepaid assets

 

 

 

2,768

 

 

 

4,361

 

Other long-term assets

 

 

 

106

 

 

 

194

 

Total

 

 

$

37,562

 

 

$

4,555

 

 

_____________

(1)
See Note 4, Commercial Manufacturing and Supply Agreement, for further details.
Schedule of Accrued Expenses

Accrued expenses as of December 31, 2023 and 2022 consisted of the following:

 

 

 

December 31,

 

 

 

2023

 

 

2022(2)

 

 

 

(in thousands)

 

Clinical studies

 

$

2,156

 

 

$

1,518

 

Other research and development

 

 

30,759

 

 

 

7,446

 

Acquired manufacturing rights (1)

 

 

25,000

 

 

 

5,000

 

Other accrued expenses

 

 

1,900

 

 

 

1,411

 

Total

 

$

59,815

 

 

$

15,375

 

______________

(1)
See Note 7, Commitments and Contingencies, Sutro Option Agreement, for further details.
(2)
The breakout and categorizations of the 2022 total accrued expenses have been updated to conform to the 2023 presentation.